IGF1 and melanoma: However, in BRAFV600E melanoma cells, SIRT6 haploinsufficiency induced resistance of melanoma cells to mitogen-activated protein kinase (MAPK) inhibitors by activating IGF signaling (100), suggesting an anti-tumor effect of SIRT6.